Niuzheng Chai

Niuzheng Chai

Auto-generated profile, based on publicly available information

Niuzheng Chai

University College London, Institute of Ophthalmology, London, UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2024 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
NBNihar Bhattacharyya
Nihar Bhattacharyya
NCNiuzheng Chai
Niuzheng Chai
NHNathaniel J. Hafford-Tear
Nathaniel J. Hafford-Tear
ASAmanda N. Sadan
Amanda N. Sadan
ASAnita Szabo
Anita Szabo
ADAlice Davidson
Alice Davidson
Fuchs endothelial corneal dystrophy (FECD) is an age-related cause of vision loss, and the most common repeat expansion-mediated disease in humans characterised to date. Up to 80% of European FECD cases have been attributed to expansion of a non-coding CTG repeat element (termed CTG18.1) located within the ubiquitously expressed transcription factor encoding gene, TCF4. The non-coding nature of the repeat and the transcriptomic complexity of TCF4 have made it extremely challenging to experimentally decipher the molecular mechanisms underlying this disease. Here we comprehensively describe CTG18.1 expansion-driven molecular components of disease within primary patient-derived corneal endothelial cells (CECs), generated from a large cohort of individuals with CTG18.1-expanded (Exp+) and CTG 18.1-independent (Exp-) FECD. We employ long-read, short-read, and spatial transcriptomic techniques to interrogate expansion-specific transcriptomic biomarkers. Interrogation of long-read sequencing and alternative splicing analysis of short-read transcriptomic data together reveals the global extent of altered splicing occurring within Exp+ FECD, and unique transcripts associated with CTG18.1-expansions. Similarly, differential gene expression analysis highlights the total transcriptomic consequences of Exp+ FECD within CECs. Furthermore, differential exon usage, pathway enrichment and spatial transcriptomics reveal TCF4 isoform ratio skewing solely in Exp+ FECD with potential downstream functional consequences. Lastly, exome data from 134 Exp- FECD cases identified rare (minor allele frequency 15) TCF4 variants in 7/134 FECD Exp- cases, suggesting that TCF4 variants independent of CTG18.1 may increase FECD risk. In summary, our study supports the hypothesis that at least two distinct pathogenic mechanisms, RNA toxicity and TCF4 isoform-specific dysregulation, both underpin the pathophysiology of FECD. We anticipate these data will inform and guide the development of translational interventions for this common triplet-repeat mediated disease.

11 February 2025 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
DADimitra Athanasiou
Dimitra Athanasiou
TATess A. V. Afanasyeva
Tess A. V. Afanasyeva
NCNiuzheng Chai
Niuzheng Chai
KZKalliopi Ziaka
Kalliopi Ziaka
KJKatarina Jovanovic
Katarina Jovanovic
MCMichael E. Cheetham
Michael E. Cheetham
Bialleleic pathogenic variants in LCA5 cause one of the most severe forms of Leber congenital amaurosis, an early-onset retinal disease that results in severe visual impairment. Here, we report the use of gene editing to generate isogenic LCA5 knock-out (LCA5 KO) induced pluripotent stem cells (iPSC) and their differentiation to retinal organoids. The molecular and cellular phenotype of the LCA5 KO retinal organoids was studied in detail and compared to isogenic controls as well as patient-derived retinal organoids. The absence of LCA5 was confirmed in retinal organoids by immunohistochemistry and western blotting. There were no major changes in retinal organoid differentiation or ciliation, however, the localisation of CEP290 and IFT88 was significantly altered in LCA5 KO and patient photoreceptor cilia with extension along the axoneme. The LCA5-deficient organoids also had shorter outer segments and rhodopsin was mislocalised to the outer nuclear layer. We also identified transcriptomic and proteomic changes associated with the loss of LCA5. Importantly, treatment with the small molecules eupatilin, fasudil or a combination of both drugs reduced CEP290 and IFT88 accumulation along the cilia. The treatments also improved rhodopsin traffic to the outer segment and reduced mislocalisation of rhodopsin in the outer nuclear layer (ONL). The improvements in cilia-associated protein localisation and traffic were accompanied by significant changes in the transcriptome towards control gene expression levels in many of the differentially expressed genes. In summary, iPSC-derived retinal organoids are a powerful model for investigating the molecular and cellular changes associated with loss of LCA5 function and highlight the therapeutic potential of small molecules to treat retinal ciliopathies.

18 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
IMIsmail Moghul
Ismail Moghul
NCNiuzheng Chai
Niuzheng Chai
NPNikolas Pontikos
Nikolas Pontikos
AHAlison Hardcastle
Alison Hardcastle
JHJavier Herrero
Javier Herrero
SBStephan Beck
Stephan Beck
Whole-genome DNA methylation (methylome) analysis is of broad interest to biomedical research due to its central role in human development and disease. However, generating high-quality methylomes at scale remains challenging due to inherent technical limitations. While imputation has the potential to help overcome this problem, no existing approach adequately addresses the scaling issue. Here, we present GIMMEcpg (Global Imputation of Mean cpg MEthylation), a novel imputation tool that scales efficiently from single samples to large cohort studies. GIMMEcpg uses a custom feature dataset built from known CpG sites within the same dataset to impute missing values by calculating the distance-weighted mean of the methylation value of the two immediately neighbouring CpG sites. We benchmarked GIMMEcpg for speed and accuracy against multiple imputation methods using downsampled datasets produced from high-quality (∼100x) Whole Genome Bisulfite Sequencing (WGBS) data. With a 10x downsampled dataset, GIMMEcpg was able to process the dataset and impute 9.14 Million CpG sites within 7 seconds (R: 0.78, MAE: +5.6%, RMSE: +10.9%). Our results demonstrate that GIMMEcpg is 39-2,562 times faster than three existing methylation imputation tools (BoostMe, DeepCpG, and MethImpute) while maintaining comparable accuracy. To quantify GIMMEcpg’s scalability, we applied it to the most extensive single collection of WGBS data (N=645 at variable coverage) from the EpiATLAS generated by the International Human Epigenome Consortium (IHEC). Using a single, standard CPU server, GIMMEcpg processed and imputed an additional 2.4 billion CpG methylation values across the 645 datasets in less than a day, enriching the EpiATLAS methylome resource by 20%. This demonstrates that GIMMEcpg scales to large cohort studies with only a subtle impact on accuracy, as illustrated by our benchmark. We also developed a machine learning variant, GIMMEcpg.ml, which delivers a higher accuracy compared to existing methodologies. Using the same 10x downsampled benchmarking dataset, GIMMEcpg.ml achieved a Person Correlation of 0.87 compared to the ground truth, representing an improvement of 0.11 over the best performing alternative method. Additionally, GIMMEcpg.ml has a Mean Absolute Error (MAE) of 8.67%, which is 2.63% lower than the most accurate performing alternative. While this enhanced accuracy comes at the cost of increased computation requirements, GIMMEcpg.ml is a useful tool where higher accuracy is preferred over scalability. For increased accessibility, GIMMEcpg is freely available under an MIT license as R and Python packages at https://github.com/ucl-medical-genomics/gimmecpg-r and https://github.com/ucl-medical-genomics/gimmecpg-python , respectively.